Cardio-oncology

 

Cardio-oncology is the cardiac care of cancer patients. Cardiac issues may develop during cancer treatment or may be pre-existing or may develop as late effects. There has been increasing recognition of these issues recently which has led to the development of the new sub-speciality of cardio-oncology bringing together cardiologists, oncologists and allied healthcare professionals.

 

This Cardio-oncology section showcases key papers in the field to allow readers to quickly familiarise themselves with the latest advances in this rapidly developing field. There will be work related to the different cardiac complications of cancer treatment e.g. acute coronary syndromes, myocarditis, heart failure and arrhythmias. Research focussing on specific cancer therapies and their cardiotoxicities will also be featured e.g. immunotherapies, targeted therapies, cytotoxic drugs, radiotherapy etc. Finally this section will enable the reader to reference the most up-to-date guidelines in the field from national and international organisations.

Close X
Other videos you might like
Dr Arjun K Ghosh

Section Advisor

Dr Arjun K Ghosh

Consultant Cardiologist, Barts Heart Centre, University College London Hospital and Hatter Cardiovascular Institute, UK

The Radcliffe cardio-oncology educational hub is an independent program led by Dr Arjun K Ghosh. Servier Laboratories Ltd has provided a grant towards the development of the cardio-oncology website but has had no input into the site’s development or content.

Recent Videos

Broadcast

Cardiac Issues in Prostate Cancer

Arjun K Ghosh, Darryl Leong, Mark Linch, et al

Video

CV Impact of Immune Checkpoint Inhibitor Cardiotoxicity

Arjun K Ghosh, Tomas Neilan,

Broadcast

How to Set up a Cardio-Oncology Service

Daniel Lenihan, Arjun K Ghosh,

Video

What to Do When the Systolic Function Falls During Breast Cancer Treatment

Arjun K Ghosh, Rebecca Dobson, Elisavet Papadimitraki , et al

Video

Cardio-oncology Discussion: Primary PCI in Cancer Patients

Arjun K Ghosh, Deepak L Bhatt, Cezar Iliescu, et al

Broadcast

5-FU Cardiotoxicity: Mechanisms and Management Strategies

Arjun K Ghosh, Mark Westwood,

Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis

Awadalla M, et al. J Am Coll Cardiol 2020;75:467-478.

Effect of Primary Percutaneous Coronary Intervention on In-Hospital Outcomes Among Active Cancer Patients Presenting With ST-Elevation Myocardial Infarction: a Propensity Score Matching Analysis

Mohamed MO et al. Eur J Acute Cardiovasc Care 2021.

Outcomes of Cardiac Resynchronization Therapy in Patients with Chemotherapy-Induced Cardiomyopathy

Ezzeddine, FM et al. Pacing Clin Electrophysiol. 2021;44(4):625-632.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Piccart M et al. J Clin Oncol. 2021;13:1448-1457.

Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study

Abdel-Qadir, H et al. J Am Heart Assoc. 2021;10(2):e018393.

Long-Term Follow-up Assessment of Cardiac Safety in SAFE-HEaRt, a Clinical Trial Evaluating the Use of HER2-Targeted Therapies in Patients With Breast Cancer and Compromised Heart Function

Khoury, K et al. Breast Cancer Res Treat. 2021;185:863–868.

Long-Term Cardiovascular Disease Mortality Among 160 834 5-Year Survivors of Adolescent and Young Adult cancer: an American Population-Based Cohort Study

Wang, L et al. Eur Heart J. 2021;42(1):101-109.

Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque

Drobni, ZD et al. Circulation. 2020;142(24):2299-2311.

The Risk of Cardiac Events in Patients Receiving Immune Checkpoint Inhibitors: a Nationwide Danish Study

D'Souza M et al. Eur Heart J. 2020;42(16):1621–1631.

Intensified Immunosuppressive Therapy in Patients With Immune Checkpoint Inhibitor-Induced Myocarditis

Cautela, J et al. J Immunother Cancer. 2020;2:e001887.

Cardio-Oncology: Twitter Chat as a Mechanism for Increasing Awareness of Heart Health for Cancer Patients

Conley, CC et al. Cardiooncology. 2020;6(19).

Increased Resting Heart Rate and Prognosis in Treatment-Naïve Unselected Cancer Patients: Results From a Prospective Observational Study

Anker, MS et al. Eur J Heart Fail. 2020;22(7):1230-1238.

A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer

Ben Kridis, W et al. Am J Clin Oncol. 2020;43(7):510-516.

Adherence to Surveillance for Second Malignant Neoplasms and Cardiac Dysfunction in Childhood Cancer Survivors: A Childhood Cancer Survivor Study

Yan, AP et al. J Clin Oncol. 2020;38(15):1711-1722.

Long-Term Outcomes of Primary Cardiac Malignancies: Multi-Institutional Results From the National Cancer Database

Sultan, I et al. J Am Coll Cardiol. 2020;75(18):2338-2347.

Classification, Prevalence, and Outcomes of Anticancer Therapy-Induced Cardiotoxicity: the CARDIOTOX Registry

López-Sendón, J et al. Eur Heart J. 2020;41(18):1720-1729.

Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis

Awadalla, M et al. J Am Coll Cardiol. 2020;75(5):467-478.

Major Cardiac Events for Adult Survivors of Childhood Cancer Diagnosed Between 1970 and 1999: Report From the Childhood Cancer Survivor Study Cohort

Mulrooney, DA et al. BMJ. 2020;368:l6794.

Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)

Alvi, RM et al. J Am Coll Cardiol. 2019;74(25):3099-3108.

A Population-Based Study of Cardiovascular Disease Mortality Risk in US Cancer Patients

Sturgeon, KM et al. Eur Heart J. 2019 Dec 21;40(48):3889-3897.

Association of Cardiac Resynchronization Therapy With Change in Left Ventricular Ejection Fraction in Patients With Chemotherapy-Induced Cardiomyopathy

Singh, JP et al. JAMA. 2019;322(18):1799-1805.

The Landscape of Cardiovascular Care in Pediatric Cancer Patients and Survivors: A Survey by the ACC Pediatric Cardio-Oncology Work Group

Ryan, TD et al. Cardiooncology. 2019;5(16).

Trends in Modes of Death in Heart Failure Over the Last Two Decades: Less Sudden Death but Cancer Deaths on the Rise

Moliner, P et al. Eur J Heart Fail. 2019;21(10):1259-1266.

Medium and Long-Term Risks of Specific Cardiovascular Diseases in Survivors of 20 Adult Cancers: A Population-Based Cohort Study Using Multiple Linked UK Electronic Health Records Databases

Strongman, H et al. Lancet. 2019;394(10203):1041-1054.

Association of Early-Stage Breast Cancer and Subsequent Chemotherapy With Risk of Atrial Fibrillation

Abdel-Qadir, H et al. JAMA Netw Open. 2019;2(9):e1911838.

An International Survey of Healthcare Providers’ Knowledge of Cardiac Complications of Cancer Treatments

Peng, J et al. Cardiooncology. 2019;5(12).

Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial

Leong, DP et al. JACC: CardioOncology 2019; 1(1):1-10.

Cancer Treatment and Survivorship Statistics, 2019

Miller, KD et al. CA Cancer J Clin. 2019;69(5):363-385.

An Evaluation of the Safety of Continuing Trastuzumab Despite Overt Left Ventricular Dysfunction

Barron, CC et al. Curr Oncol. 2019;26(4):240-246.

The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study

Abdel-Qadir, H et al. J Natl Cancer Inst. 2019;111(8):854-862.

Takotsubo Syndrome in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A New Adverse Cardiac Complication

Ederhy, S et al. Eur J Heart Fail. 2019;21(7):945-947.

Increasing Evidence for and a Word of Caution About an Association Between Cancer and Congenital Heart Disease

Gurvitz, M et al. JAMA Netw Open. 2019;2(7):e196756.

Risk of Cancer Among Children and Young Adults With Congenital Heart Disease Compared With Healthy Controls

Mandalenakis, Z et al. JAMA Netw Open. 2019;2(7):e196762.

6 Months Versus 12 Months of Adjuvant Trastuzumab in Early Breast Cancer (PHARE): Final Analysis of a Multicentre, Open-Label, Phase 3 Randomised Trial

Pivot, X et al. Lancet. 2019;393(10191):2591-2598.

Prospective Evaluation of the Cardiac Safety of HER2-Targeted Therapies in Patients With HER2-Positive Breast Cancer and Compromised Heart Function: The SAFE-HEaRt Study

Lynce, F et al. Breast Cancer Res Treat. 2019;175(3):595-603.

A Quality Improvement Approach to Reducing Hospital Readmissions in Patients With Cancer and Heart Failure

Fadol, A et al. Cardiooncology. 2019;5(5).

Therapy-Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study

Bates, JE et al. J Clin Oncol. 2019;37(13):1090-1101.

Paediatric Cardio-Oncology: Epidemiology, Screening, Prevention, and Treatment

Chow, EJ et al. Cardiovasc Res. 2019;115(5):922-934.

Upfront Dexrazoxane for the Reduction of Anthracycline-Induced Cardiotoxicity in Adults With Preexisting Cardiomyopathy and Cancer: A Consecutive Case Series

Ganatra, S et al. Cardiooncology. 2019;5(1).

Common Mechanistic Pathways in Cancer and Heart Failure. A Scientific Roadmap on Behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

de Boer, RA et al. Eur J Heart Fail. 2020;22(12):2272-2289.

Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement From the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology

Pudil, R et al. Eur J Heart Fail. 2020;22(11):1966-1983.

Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer

Ehrhardt, MJ et al. J Clin Oncol. 2020;38(33):3851-3862.

Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association

Tisdale, JE et al. Circulation. 2020;142(15):e214-e233.

Management of Cardiac Disease in Cancer Patients Throughout Oncological Treatment: ESMO Consensus Recommendations

Curigliano, G et al. Ann Oncol. 2020;31(2):171-190.

Correction to: Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association

Circulation. 2019;140(9):e543.

Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association

Gilchrist, SC et al. Circulation. 2019;139(21):e997-e1012.

Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association

Campia, U et al. Circulation. 2019;139(13):e579-e602.

Transdermal Oestradiol for Androgen Suppression in Prostate Cancer: Long-Term Cardiovascular Outcomes From the Randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) Trial Programme

Langley RE et al. Lancet. 2021;397(10274):581-591.

Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy

Thavendiranathan P et al. J Am Coll Cardiol. 2021;77(4):392-401.

Real-Time Exercise Reduces Impaired Cardiac Function in Breast Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial

Chung WP et al. Ann Phys Rehabil Med. 2021:101485.

Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 1 Year Results of the SUCCOUR Trial

T Negishi et al. European Heart Journal. 2020;41(2): ehaa946.3282.

Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA): End-of-Study Results From a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Study

Swain SM et al. Lancet Oncol. 2020;21(4):519-530.

Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study

Kolberg HC et al. Drug Saf. 2020;43(3):233-242.

Anthracycline-Induced Cardiotoxicity Prevention With Angiotensin-Converting Enzyme Inhibitor Ramipril in Women With Low-Risk Breast Cancer: Results of a Prospective Randomized Study

Słowik A et al. Kardiol Pol. 2020;78(2):131-137.

6 Versus 12 Months of Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer (PERSEPHONE): 4-Year Disease-Free Survival Results of a Randomised Phase 3 Non-Inferiority Trial

Earl HM et al. Lancet. 2019;393(10191):2599-2612.

Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer

Guglin M et al. J Am Coll Cardiol. 2019;73(22):2859-2868.

Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial

Nabati M et al. J Cardiovasc Pharmacol Ther. 2019;24(3):233-241.

Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review

Rao VU et al. J Am Coll Cardiol 2021;77(21):2693-2716.

Effects of Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Use on Cancer Therapy-Related Cardiac Dysfunction: A Meta-Analysis of Randomized Controlled Trials

Fang K et al. Heart Fail Rev. 2021;26(1):101-109.

Review of Late CV Effects After Hematopoietic Stem Cell Transplantation

Ryan TD et al. ACC Expert Analysis, Jan 25, 2021.

Management of Immune Checkpoint Inhibitor–Induced Myocarditis: The French Working Group’s Plea for a Pragmatic Approach

Thuny F et al. J Am Coll Cardiol CardioOnc 2021;3(1):157-161.

The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer

Zhang L et al. J Am Coll Cardiol CardioOnc 2021:3(1);35-47.

Comparative Efficacy and Safety of Trastuzumab Biosimilars to the Reference Drug: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Cargnin S et al. Cancer Chemother Pharmacol. 2020;86(5):577-588.

Adverse Cardiac Effects of Cancer Therapies: Cardiotoxicity and Arrhythmia

Herrmann J et al. Nat Rev Cardiol. 2020;17(8):474-502.

Adverse Cardiac Events in the Treatment of Non-Small Cell Lung Cancer With Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: A Protocol for Systematic Review and Meta-Analysis

Li H et al. Medicine (Baltimore). 2020;99(32):e21613.

The Novel Coronavirus Disease (COVID-19) Threat for Patients With Cardiovascular Disease and Cancer

Ganatra S et al. JACC CardioOncol. 2020;2(2):350-355.

Challenges and Solutions in Management of Cardiotoxicity Induced by Checkpoint Inhibitors

Beáta M et al. Klin Onkol. 2020;33(5):350-355.

Six Months vs. 12 Months of Adjuvant Trastuzumab Among Women With HER2-Positive Early-Stage Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

Deng H et al. Front Oncol. 2020;10:288.

Role of Cardioprotective Agents on Chemotherapy-Induced Heart Failure: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Li X et al. Pharmacol Res. 2020;151:104577.

Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease

Aboumsallem JP et al. J Am Heart Assoc. 2020;9(2):e013754.

Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives

Ganatra S et al. J Am Coll Cardiol. 2019;74(25):3153-3163.

Cardio-Oncology: Low-Grade Inflammation as a Common Pathway of Cancer and Cardiovascular Disease

Lüscher TF et al. Eur Heart J. 2019;40(48):3871-3874.

Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week

Ball S et al. J Am Coll Cardiol. 2019;74(13):1714-1727.

Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis

Oikonomou EK et al. JAMA Cardiol. 2019;4(10):1007-1018.

Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy

Vaduganathan M et al. JACC CardioOncol. 2019;1(1):54-65.

Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week

Libby P et al. J Am Coll Cardiol. 2019;74(4):567-577.

Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Bonaca MP et al. Circulation. 2019;140(2):80-91.

Cardio-Oncology Services: Rationale, Organization, and Implementation

Lancellotti P et al. Eur Heart J. 2019;40(22):1756-1763.

Bidirectional Relationship Between Cancer and Heart Failure: Old and New Issues in Cardio-oncology

Bertero E et al. Card Fail Rev. 2019;5(2):106-111.

Common Risk Factors for Heart Failure and Cancer

Meijers WC et al. Cardiovasc Res. 2019;115(5):844-853.

5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer

Abdel-Rahman O et al. Clin Colorectal Cancer. 2019;18(1):58-63.

Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions

Interventional Cardiology Review 2019;14(2):89–94.

Bidirectional Relationship Between Cancer and Heart Failure: Old and New Issues in Cardio-oncology

Cardiac Failure Review 2019;5(2):106–11.

Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients

Cardiac Failure Review 2019;5(2):112–8.

Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome

US Cardiology Review 2019;13(2):74–82.

Subclinical Left Ventricular Dysfunction During Chemotherapy

Cardiac Failure Review 2019;5(1):31–6.

The Future Role of Cardio-oncologists

Cardiac Failure Review 2017;3(2):140–2.

Cancer and Heart Failure: Understanding the Intersection

Cardiac Failure Review 2017;3(1):66–70.

Cardiac Toxicity of Cancer Chemotherapy

US Cardiology Review 2017;11(1):20–4

Cardiotoxicity: Precision Medicine With Imprecise Definitions

Chung R et al. Open Heart 2018;5(2):e000774.

Risk of Atrial Fibrillation According to Cancer Type: A Nationwide Population-Based Study

Yun J et al. J Am Coll Cardiol CardioOnc. 2021; 3(2), 221–232.

Pericardial Disease in Cancer Patients

Ghosh AK et al. Current Treatment Options in Cardiovascular Medicine 2018,20(7):60.

Hypertensive Cardiotoxicity in Cancer Treatment—Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies—Epidemiology, Incidence, and Pathophysiology

Chung R et al. Journal of Clinical Medicine 2020;9(10):3346.

Cardiac Computed Tomography in Cardio-Oncology: An Update on Recent Clinical Applications

Rominin S et al. EHJ Cardiovascular Imaging 2021;22(4):397–405.

Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer

Atkins KM et al. JAMA Oncol. 2021;7(2):206-219.

Cardiovascular care of the oncology patient during COVID-19: An expert consensus document from the ACC Cardio-Oncology and Imaging Councils

Baldassarre, LA et al. J Natl Cancer Inst. 2020;113(5):513-522.

Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the Eur

Čelutkienė J et al. Eur J Heart Fail. 2020;22(9):1504-1524.

Cardiotoxicity and Myocardial Hypoperfusion Associated With Anti-Vascular Endothelial Growth Factor Therapies: Prospective Cardiac Magnetic Resonance Imaging in Patients With Cancer

Dobbin SJH et al. Eur J Heart Fail. 2020;22(7):1276-1277.

No Increased Cardiac Mortality or Morbidity of Radiation Therapy in Breast Cancer Patients After Breast-Conserving Surgery: 20-Year Follow-up of the Randomized SweBCGRT Trial

Killander F et al. Int J Radiat Oncol Biol Phys. 2020;107(4):701-709.

Modified Routine Cardiac Imaging Surveillance of Adult Cancer Patients and Survivors During the COVID-19 Pandemic

Calvillo-Argüelles O et al. JACC CardioOncol. 2020;2(2):345-349.

Longitudinal Changes in Echocardiographic Parameters of Cardiac Function in Pediatric Cancer Survivors

Border WL et al. JACC CardioOncol. 2020;2(1):26-37.

Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy

Upshaw JN et al. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):198-210.

Cardiac Toxicity in Operable Esophageal Cancer Patients Treated With or Without Chemoradiation

Witt JS et al. Am J Clin Oncol. 2019;42(8):662-667.

Statin Use and Risk of Vascular Events Among Cancer Patients After Radiotherapy to the Thorax, Head, and Neck

Boulet J et al. J Am Heart Assoc. 2019;8(13):e005996.

Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer

Atkins KM et al. J Am Coll Cardiol. 2019 Jun 18;73(23):2976-2987.

No Increased Cardiac Mortality or Morbidity of Radiation Therapy in Breast Cancer Patients After Breast-Conserving Surgery: 20-Year Follow-up of the Randomized SweBCGRT Trial

Killander F et al. Int J Radiat Oncol Biol Phys. 2020;107(4):701-709.

British Society of Echocardiography and British Cardio-Oncology Society Cardio-Oncology guidelines JACC Cardio-Oncology and Echo Research and Practice (joint publication) 2021 (in press)

Dobson R, et al. Echo Research and Practice 2021; 8(1): G1-G18.

Implementation of Cardio-Oncology Training for Cardiology Fellows

Tuzovic M, et al, J Am Coll Cardiol CardioOnc. 2020;2(5):795–799.

Implementation of Cardio-Oncology Training for Cardiology Fellows

JACC Cardio-Oncology 2020;2(5):795-799.

Cardio-Oncology Education and Training: JACC Council Perspectives

Alvarez-Cardona JA et al. J Am Coll Cardiol. 2020;76(19):2267-2281.

Chrysanthemum morifolium Extract Prevents the Development of Doxorubicin-induced Heart Failure

European Cardiology Review 2021;16:e65.

AF in Cancer Patients: A Different Need for Anticoagulation?

European Cardiology Review 2019;14(1):65–7

Guest Editorial: Is Cardio-oncology Ready for Algorithms?

European Cardiology Review 2018;13(1):62–3.

Cardio-oncology: A Focus on Cardiotoxicity

European Cardiology Review 2018;13(1):64–9.